On Friday, Smith & Nephew ADR reached a key performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 84, up from 79 the day before.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
History reveals that the best-performing stocks often have an 80 or higher RS Rating in the early stages of their moves.
Smith & Nephew ADR is building a consolidation with a 31.72 buy point. See if it can clear the breakout price in heavy trade.
The company posted -2% EPS growth in the latest quarterly report, while sales growth came in at 6%.
The company earns the No. 18 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
